Online inquiry

IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12923MR)

This product GTTS-WQ12923MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12923MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1246MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ573MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ13207MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ15172MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA T1h
GTTS-WQ9248MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ6163MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ15405MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ7092MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW